OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
June 01, 2024 08:00 ET
|
OkayCoin
Los Angeles, CA, USA, June 01, 2024 (GLOBE NEWSWIRE) -- OkayCoin, a pioneering force in the cryptocurrency staking sphere, today announced a series of strategic initiatives aimed at maximizing...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024 08:00 ET
|
Kymera Therapeutics, Inc.
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement...
Kaskela Law LLC Announces Shareholder Investigation of WideOpenWest, Inc. (NYSE: WOW) and Encourages Investors to Contact the Firm
June 01, 2024 08:00 ET
|
Kaskela Law
PHILADELPHIA, June 01, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating WideOpenWest, Inc. (NYSE: WOW) on behalf of the company’s shareholders. WideOpenWest shareholders...
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
June 01, 2024 08:00 ET
|
Purple Biotech Ltd.
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs....
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
June 01, 2024 08:00 ET
|
Molecular Partners
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024 08:00 ET
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
June 01, 2024 08:00 ET
|
CryptoHeap
Miami, Fl, June 01, 2024 (GLOBE NEWSWIRE) -- CryptoHeap, an innovative leader in cryptocurrency staking services, today announced its ambitious goal to become the top crypto staking platform as...
ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
June 01, 2024 07:55 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, June 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Enphase class action lawsuit, captioned Bialic v. Enphase Energy, Inc., No....
Il documentario Life at the Yellow River Delta vince ai Telly Awards
June 01, 2024 07:01 ET
|
Shandong Radio and Television Station
DONGYING, Cina, June 01, 2024 (GLOBE NEWSWIRE) -- Il 21 maggio 2024, in occasione della 45a edizione dei Telly Awards, l’edizione internazionale del documentario Life at the Yellow River Delta della...
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
June 01, 2024 07:00 ET
|
Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today...
- May 31, 2024 21:13 ET 2024 Canadian Screen Award Winners Announced
- May 31, 2024 20:59 ET BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action